Sclerosis: all 3,103 studies
Page 29 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00748501Phase 2
- A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady StateCompletedNCT00744679Phase 4
- CDP323 Biomarker StudyCompletedNCT00726648Phase 1/2
- Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient PopulationCompletedNCT00718497
- EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00718458
- Pennsylvania Consortium: Clinical DatabaseTerminatedNCT00718445
- Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00718393
- Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive TechnologyTerminatedNCT00718107
- Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) PatientTerminatedNCT00718016
- Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).TerminatedNCT00718003
- Amyotrophic Lateral Sclerosis (ALS) Tissue Donation ProgramCompletedNCT00716131
- Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00714805
- Cerebrospinal Fluid RepositoryCompletedNCT00714636
- Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00714220
- Lido Workset StudyCompletedNCT00710645
- Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual DysfunctionCompletedNCT00707187Phase 2
- Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral SclerosisCompletedNCT00706147Phase 2/3
- Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
- Gene Expression Profiles in Multiple Sclerosis (MS)CompletedNCT00704834
- Recombinant Human Relaxin in the Treatment of Diffuse SclerodermaCompletedNCT00704665Phase 3
- A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without TreatmentCompletedNCT00702065
- Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)CompletedNCT00695084Phase 1
- A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00694941Phase 2
- Study of Pioglitazone in Patients With Amyotrophic Lateral SclerosisTerminatedNCT00690118Phase 2
- Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)TerminatedNCT00688948Phase 2/3
- Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00677768
- A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple SclerosisCompletedNCT00676156Phase 1
- Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)Status unknownNCT00674934Phase 1
- Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)Status unknownNCT00673140Phase 1
- Angiogenic/Angiostatic Mediators in Patients With Systemic SclerosisCompletedNCT00668473
- Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to PlaceboCompletedNCT00668343Phase 3
- Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic SclerosisCompletedNCT00667134
- Minocycline in Clinically Isolated Syndromes (CIS)CompletedNCT00666887Phase 3
- Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple SclerosisCompletedNCT00645749Phase 1
- Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple SclerosisCompletedNCT00644904Phase 1/2
- Memantine Therapy for Multiple SclerosisTerminatedNCT00638833Phase 2
- Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MSTerminatedNCT00638196Phase 1
- Growth Hormone in Amyotrophic Lateral SclerosisCompletedNCT00635960Phase 2
- Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.WithdrawnNCT00630383Phase 2
- Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple SclerosisCompletedNCT00629642Phase 4
- Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic SclerosisTerminatedNCT00628797Phase 1/2
- Sildenafil for Treatment of Digital Ulcers in Patients With Systemic SclerosisCompletedNCT00624273Phase 2
- Flupirtine as Oral Treatment in Multiple SclerosisTerminatedNCT00623415Phase 2
- Effect of Different Iloprost Doses on Symptoms in Systemic SclerosisTerminatedNCT00622687Phase 2
- Management of Pain in Persons With Multiple SclerosisCompletedNCT00621374Not applicable
- Combination Therapy Using Cellcept and Rebif in RRMSCompletedNCT00618527Early Phase 1
- Pulmonary Arterial Hypertension in Systemic SclerosisStatus unknownNCT00617487
- AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MSCompletedNCT00617383
- 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis PatientsCompletedNCT00616733Phase 1
- Atorvastatin in Relapsing-Remitting Multiple SclerosisCompletedNCT00616187Phase 2
- R(+)PPX High Dose Treatment of ALSCompletedNCT00600873Phase 1/2
- Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple SclerosisCompletedNCT00599274
- Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsCompletedNCT00598455
- Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/DayTemporarily not availableNCT00596115
- Pulmonary Artery Remodelling With BosentanCompletedNCT00595049Phase 4
- Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)CompletedNCT00594087Not applicable
- Dose-Escalation Study of T Cell Vaccine in Multiple SclerosisCompletedNCT00587691Phase 1/2
- QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic SclerosisTerminatedNCT00581997Phase 2
- Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00580593Phase 1
- Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic SclerosisCompletedNCT00574613Phase 2
- How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full DoseTerminatedNCT00574041Phase 4
- Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral SclerosisStatus unknownNCT00563537Phase 1
- A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALSWithdrawnNCT00561366Phase 2
- Non-Invasive Ventilation in Amyotrophic Lateral SclerosisStatus unknownNCT00560287Phase 4
- Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
- Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
- MUltiple Sclerosis and Extract of Cannabis (MUSEC) StudyTerminatedNCT00552604Phase 3
- Firategrast (SB683699) Surface Area Study in Multiple Sclerosis PatientsCompletedNCT00548769Phase 1
- BENEFIT Extension StudyCompletedNCT00544037
- Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00537641
- Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?CompletedNCT00534261Phase 4
- Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple SclerosisTerminatedNCT00532532Phase 2
- A Study of C105 on Cognitive Dysfunction in Persons With Multiple SclerosisCompletedNCT00529581Phase 2
- Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)CompletedNCT00525668Phase 1/2
- Avonex 15 Year Long Term Follow-up StudyCompletedNCT00525343
- Promoting Physical Activity for Persons With Multiple SclerosisCompletedNCT00513448Not applicable
- Whole Body Vibration Therapy in Participants With MS Related Balance DeficitsCompletedNCT00510523Not applicable
- A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose NaltrexoneCompletedNCT00501696Phase 3
- Visual Impairment, Oscillopsia and Multiple SclerosisTerminatedNCT00498199
- Allogeneic Stem Cell Transplantation for the Treatment of Multiple SclerosisWithdrawnNCT00497952Phase 1/2
- Tysabri Observational ProgramCompletedNCT00493298
- Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon BetaCompletedNCT00493116Phase 4
- Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta TherapyCompletedNCT00493077Phase 4
- Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple SclerosisCompletedNCT00492765Phase 4
- GER-009-06-AVX Early Therapy in Multiple SclerosisCompletedNCT00492570
- Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing AntibodiesCompletedNCT00492466Phase 4
- Comparison of Bone Effects With Copaxone and Interferon in Multiple SclerosisCompletedNCT00490906
- Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMStatus unknownNCT00490789Phase 2
- IPX056 in Subjects With Established Spasticity Resulting From Multiple SclerosisCompletedNCT00488839Phase 3
- Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323TerminatedNCT00484536Phase 2
- TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of WorldCompletedNCT00483847
- Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple SclerosisCompletedNCT00480181Phase 4
- TYSABRI Global Observational Program in SafetyCompletedNCT00477113
- Optimizing IFN Beta - 1B DoseCompletedNCT00473213Phase 3
- Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple SclerosisCompletedNCT00469378Phase 2
- Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisTerminatedNCT00468611Phase 3
- Modulation of Plasmacytoid Dendritic Cell Function in Multiple SclerosisCompletedNCT00468182
- One Year Extension Study To Protocol C2/5/TZ:MS-05TerminatedNCT00464958Phase 1/2
- Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MSCompletedNCT00463710
- Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With BetaseronCompletedNCT00461396